AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

AbbVie’s neuroscience portfolio is also contributing to top-line growth. Sales of its neuroscience drugs increased 20.3% to ...

MoneyShow presents top investment ideas for 2026 from leading advisors. Part 1 includes AbbVie, Alexandria Real Estate ...

The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest ...

AbbVie recently reported that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir) for treating acute and chronic ...

AbbVie said on Monday that it has struck a three-year deal with U.S. President Donald Trump's administration to reduce drug ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

Billionaire and celebrity entrepreneur Mark Cuban has revealed his latest move to tackle the cost of medicines in the US, agreeing a deal to make a low-cost biosimilar version of AbbVie’s blockbuster ...

AbbVie (NYSE: ABBV) today announced a voluntary agreement with the Trump administration to further advance access and affordability for Americans while protecting and investing in U.S. pharmaceutical ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

These robust surges underscore AbbVie’s ability for swift gains, indicating that upcoming catalysts could propel the stock to ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...